EvolutionaryScale Analysis: $142M Raised

EvolutionaryScale envisions a future where AI significantly enhances the understanding of complex biological systems, facilitates new scientific discoveries, and contributes to drug design and sustainability. While they do not provide specific numerical predictions for the AI industry in 2025, their focus on developing multimodal models indicates a commitment to integrating biological data and advancing AI applications in life sciences.

EvolutionaryScale offers several key products and services in the AI sector, primarily focused on protein sequence modeling. Their main offerings include:

1. ESM Cambrian: A model that delivers breakthrough performance in protein sequence modeling and sets a new state of the art for representation learning.
2. ESM3: A generative language model designed to help scientists understand, imagine, and create proteins. It can generate novel proteins, such as esmGFP, a new version of the Green Fluorescent Protein, showcasing its emergent reasoning capabilities over protein properties like sequence, structure, and function.
3. API Access: ESM3 models are available through an API and partner platforms, including a small model called ESM3-open, which is available under a non-commercial license on GitHub.
4. Cloud Availability: ESM3 is accessible on AWS via Sagemaker and will be available on Omics platform and AWS Bedrock, as well as through NVIDIA's BioNemo and NIM microservice.

These products are aimed at advancing scientific discovery and understanding in the life sciences.

EvolutionaryScale's headquarters is located at 853 Broadway, New York, NY 10003, United States.